# A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multi

Source: https://onco.cc/trials/nct05535244/  
OnCo record `nct05535244` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Cevostamab, Tocilizumab in multiple myeloma, run by Hoffmann-La Roche, active and no longer recruiting.

## Summary

A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma is a phase 1/2 interventional study registered as NCT05535244 by Hoffmann-La Roche, with 90 participants planned, started 2022-10-17 and due to reach its primary completion in 2027-02-26. Interventions recorded: Cevostamab, Tocilizumab. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05535244
- Phase: 1/2
- Setting: A Phase I/II, Open-Label, Multi-Cohort Study to Evaluate the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen-Exposed Patients With Relapsed/Refractory Multiple Myeloma
- Sponsor: Hoffmann-La Roche
- Enrolled: 90

## Sources

- ClinicalTrials.gov NCT05535244: https://clinicaltrials.gov/study/NCT05535244

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- drugs: [Cevostamab](https://onco.cc/drugs/cevostamab/), [Tocilizumab](https://onco.cc/drugs/tocilizumab/)
- companies: [Roche / Genentech](https://onco.cc/companies/roche-genentech/)

---
JSON: https://onco.cc/api/v1/entities/nct05535244.json